Andarix appoints experts to help in the development of P2045

08/1/2011 | PR Web

Andarix Pharmaceuticals has appointed new clinical oncology experts to its clinical advisory board to help with the development of its lead drug candidate, P2045. The drug is a treatment for lung and other cancers and is based on a radiolabeled somatostatin peptide analogue.

View Full Article in:

PR Web

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN